Carol O’Brien

4.2k citations

31 papers · 2.4k · h-index 19

Impact in

Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
Oncology top 5%
- HER2/EGFR in Cancer Research

Papers in

Molecular Biology 19
- PI3K/AKT/mTOR signaling in cancer 10
- Melanoma and MAPK Pathways 3
Oncology 8
- HER2/EGFR in Cancer Research 4

Co-authors: Mark R. Lackner (21 shared papers)Lukas C. Amler (11 shared papers)Lori S. Friedman (8 shared papers)Jill M. Spoerke (12 shared papers)Marcia Belvin (4 shared papers)Leanne Berry (4 shared papers)Heidi Savage (10 shared papers)Guy Cavet (4 shared papers)
Journals: Cancer Research (7 papers)Molecular Cancer Therapeutics (4 papers)Clinical Cancer Research (4 papers)Science Signaling (2 papers)Genes & Cancer (1 paper)
Partner nations: United States Ireland France

In The Last Decade

Carol O’Brien

31 papers receiving 2.3k citations

Peers

Countries citing papers authored by Carol O’Brien

Since Specialization

Citations

This map shows the geographic impact of Carol O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol O’Brien more than expected).

Fields of papers citing papers by Carol O’Brien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol O’Brien. The network helps show where Carol O’Brien may publish in the future.

Co-authors

The 25 scholars most cited alongside Carol O’Brien, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Carol O’Brien Line = papers co-authored together Carol O’Brien links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models Clinical Cancer Research ·Klaus P. Hoeflich, Carol O’Brien, Zachary Boyd, Guy Cavet, Steve Guerrero, Kenneth Jung, Tom Januario, Heidi Savage, Elizabeth A. Punnoose, Tom Truong, Wei Zhou, Leanne Berry, Lesley Murray, Lukas C. Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner	2009	385
2	TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer Science Signaling ·Susanna Stinson, Mark R. Lackner, Alex Adai, Nancy Yu, Hyo‐Jin Kim, Carol O’Brien, Jill M. Spoerke, Suchit Jhunjhunwala, Zachary Boyd, Thomas Januario, Robert Newman, Yue Peng, Richard Bourgon, Zora Modrušan, Howard M. Stern, Søren Warming, Frédéric J. de Sauvage, Lukas C. Amler, Ru‐Fang Yeh, David Dornan	2011	252
3	De novo mutations in schizophrenia implicate chromatin remodeling and support a genetic overlap with autism and intellectual disability Molecular Psychiatry ·Siobhan McCarthy, Jesse Gillis, Melissa Kramer, Jayon Lihm, Seungtai Yoon, Yael Berstein, Meeta Mistry, Paul Pavlidis, Richard Solomon, Elena Ghiban, Eric Antoniou, Eric Kelleher, Carol O’Brien, Gary Donohoe, Michael Gill, Derek W. Morris, W. Richard McCombie, Aiden Corvin	2014	242
4	Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models Clinical Cancer Research ·Carol O’Brien, Jeffrey J. Wallin, Deepak Sampath, Debraj GuhaThakurta, Heidi Savage, Elizabeth A. Punnoose, Jane Guan, Leanne Berry, Wei Wei Prior, Lukas C. Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner	2010	201
5	Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes Molecular Cancer Research ·Xiaolan Hu, Howard M. Stern, Lin Ge, Carol O’Brien, Lauren E. Haydu, Cynthia D. Honchell, Peter M. Haverty, Brock A. Peters, Thomas D. Wu, Lukas C. Amler, John Chant, David Stokoe, Mark R. Lackner, Guy Cavet	2009	177
6	ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors Molecular Cancer Therapeutics ·Georgia Hatzivassiliou, Bonnie Liu, Carol O’Brien, Jill M. Spoerke, Klaus P. Hoeflich, Peter M. Haverty, Robert Soriano, William F. Forrest, Sherry Heldens, Huifen Chen, Karen Toy, Connie Ha, Wei Zhou, Kyung Song, Lori S. Friedman, Lukas C. Amler, Garret M. Hampton, John G. Moffat, Marcia Belvin, Mark R. Lackner	2012	155
7	Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models Clinical Cancer Research ·Jill M. Spoerke, Carol O’Brien, Ling Huw, Hartmut Koeppen, Jane Fridlyand, Rainer K. Brachmann, Peter M. Haverty, Ajay Pandita, Sankar Mohan, Deepak Sampath, Lori S. Friedman, Leanne Ross, Garret M. Hampton, Lukas C. Amler, David S. Shames, Mark R. Lackner	2012	149
8	Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression Cancer Research ·Klaus P. Hoeflich, Sylvia Herter, Janet Tien, Leo Lap-Yan Wong, Leanne Berry, Jocelyn Chan, Carol O’Brien, Zora Modrušan, Somasekar Seshagiri, Mark R. Lackner, Howard M. Stern, Edna F. Choo, Lesley Murray, Lori S. Friedman, Marcia Belvin	2009	144
9	miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast CancerA presentation from the Keystone Symposium on Epithelial Plasticity and Epithelial to Mesenchymal Transition, Vancouver, Canada, 21 to 26 January 2011. This Presentation also complements the Science Signaling Research Article by Stinson et al. published 14 June 2011. Science Signaling ·Susanna Stinson, Mark R. Lackner, Alex Adai, Nancy Yu, Hyojin Kim, Carol O’Brien, Jill M. Spoerke, Suchit Jhunjhunwala, Zachary Boyd, Thomas Januario, Robert Newman, Yue Peng, Richard Bourgon, Zora Modrušan, Howard M. Stern, Søren Warming, Frédéric J. de Sauvage, Lukas C. Amler, Ru‐Fang Yeh, David Dornan	2011	118
10	Functional Genomics Identifies ABCC3 as a Mediator of Taxane Resistance in HER2-Amplified Breast Cancer Cancer Research ·Carol O’Brien, Guy Cavet, Ajay Pandita, Xiaolan Hu, Lauren E. Haydu, Sankar Mohan, Karen Toy, Celina Sanchez Rivers, Zora Modrušan, Lukas C. Amler, Mark R. Lackner	2008	88
11	Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer Molecular Cancer Therapeutics ·Jiping Zha, Carol O’Brien, Heidi Savage, Ling‐Yuh Huw, Fiona Zhong, Leanne Berry, Gail D. Lewis Phillips, Elizabeth Luis, Guy Cavet, Xiaolan Hu, Lukas C. Amler, Mark R. Lackner	2009	66
12	Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer Oncogenesis ·L-Y Huw, Carol O’Brien, Ajay Pandita, S. Mohan, Jill M. Spoerke, Shan Lu, Yulei Wang, Garret M. Hampton, Timothy R. Wilson, Mark R. Lackner	2013	66
13	PTEN Loss Is Associated with Worse Outcome in HER2 -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance Clinical Cancer Research ·Howard M. Stern, Humphrey Gardner, Tomasz Burzykowski, Wafaa Elatre, Carol O’Brien, Mark R. Lackner, Gary A. Pestano, Angela Santiago, Ivonne Villalobos, W. Eiermann, Tadeusz Pieńkowski, Miguel Martín, Nicholas J. Robert, John Crown, Paolo Nucíforo, Valerie Bée, John R. Mackey, Dennis J. Slamon, Michael F. Press	2015	57
14	Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β Cancer Research ·Yoshito Nakanishi, Kimberly Walter, Jill M. Spoerke, Carol O’Brien, Ling Huw, Garret M. Hampton, Mark R. Lackner	2016	55
15	Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays Molecular Cancer Therapeutics ·Zachary Boyd, Qun Wu, Carol O’Brien, Jill M. Spoerke, Heidi Savage, Paul J. Fielder, Lukas C. Amler, Yibing Yan, Mark R. Lackner	2008	51
16	Effects of MIR137 on fronto-amygdala functional connectivity NeuroImage ·Omar Mothersill, Derek W. Morris, Sinéad Kelly, Emma J. Rose, Ciara Fahey, Carol O’Brien, Ronan Lyne, Richard B. Reilly, Michael Gill, Aiden Corvin, Gary Donohoe	2013	39
17	Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers PLoS ONE ·Erica Schleifman, Rupal Desai, Jill M. Spoerke, Yuanyuan Xiao, Cheryl V. Wong, Ilma Abbas, Carol O’Brien, R. D. Patel, Teiko Sumiyoshi, Ling Fu, Rachel N. Tam, Hartmut Koeppen, Timothy R. Wilson, Rajiv Raja, Garret M. Hampton, Mark R. Lackner	2014	30
18	The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population npj Breast Cancer ·Timothy R. Wilson, Jianjun Yu, Xuyang Lu, Jill M. Spoerke, Yuanyuan Xiao, Carol O’Brien, Heidi Savage, Ling‐Yuh Huw, Wei Zou, Hartmut Koeppen, William F. Forrest, Jane Fridlyand, Ling Fu, Rachel Tam, Erica Schleifman, Teiko Sumiyoshi, Luciana Molinero, Garret M. Hampton, Joyce O’Shaughnessy, Mark R. Lackner	2016	25
19	High-throughput proteomics and in vitro functional characterization of the 26 medically most important elapids and vipers from sub-Saharan Africa GigaScience ·Giang Thi Tuyet Nguyen, Carol O’Brien, Yessica Wouters, Lorenzo Seneci, Alex Gallissà-Calzado, Isabel Campos-Pinto, Shirin Ahmadi, Andreas H. Laustsen, Anne Ljungars	2022	22
20	The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase Genes & Cancer ·Klaus P. Hoeflich, Jane Guan, Kyle A. Edgar, Carol O’Brien, Heidi Savage, Timothy R. Wilson, Richard M. Neve, Lori S. Friedman, Jeffrey J. Wallin	2016	15

About Carol O’Brien

Carol O’Brien is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Genetics, having authored 31 papers that have together received 2.4k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (10 papers), Chronic Lymphocytic Leukemia Research (6 papers), Cancer Genomics and Diagnostics (5 papers), HER2/EGFR in Cancer Research (4 papers), Melanoma and MAPK Pathways (3 papers), Lung Cancer Treatments and Mutations (3 papers), Cancer Mechanisms and Therapy (3 papers) and MicroRNA in disease regulation (2 papers). The work is most often cited by research in Cancer Research (667 citations), Oncology (782 citations), Molecular Biology (1.7k citations), Genetics (178 citations) and Pathology and Forensic Medicine (231 citations). Carol O’Brien has collaborated with scholars based in United States, Ireland and France. Frequent co-authors include Mark R. Lackner, Lukas C. Amler, Lori S. Friedman, Jill M. Spoerke, Marcia Belvin, Leanne Berry, Heidi Savage, Guy Cavet, Zachary Boyd and Howard M. Stern. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Clinical Cancer Research, Science Signaling and Genes & Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Carol O’Brien

Impact in

Papers in i

In The Last Decade

Carol O’Brien

Peers

Countries citing papers authored by Carol O’Brien

Fields of papers citing papers by Carol O’Brien

All Works

About Carol O’Brien

Explore authors with similar magnitude of impact

Papers in